Halozyme Therapeutics (HALO) EBT Growth (3y) (2013 - 2026)
Halozyme Therapeutics (HALO) EBT Growth (3y) (2013 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | 9.34% |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 40.43% |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 12.01% |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | -1.05% |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 86.16% |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | - |
| 10 | Halozyme Therapeutics | 9.55 Bn | 9.23 Bn | 297.47 Mn | 51.13% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 51.13% |
| Dec 31, 2025 | -50.73% |
| Sep 30, 2025 | 43.75% |
| Jun 30, 2025 | 89.72% |
| Mar 31, 2025 | 24.57% |
| Dec 31, 2024 | 48.15% |
| Sep 30, 2024 | 30.62% |
| Jun 30, 2024 | 8.76% |
| Mar 31, 2024 | 50.65% |
| Dec 31, 2023 | 11.37% |
| Sep 30, 2023 | 41.04% |
| Jun 30, 2023 | 53.27% |
| Mar 31, 2023 | 119.50% |
| Dec 31, 2022 | 59.46% |
| Sep 30, 2022 | 70.40% |
| Jun 30, 2022 | 59.46% |
| Mar 31, 2022 | 244.62% |
| Dec 31, 2021 | 218.46% |
| Sep 30, 2021 | 67.04% |
| Jun 30, 2021 | 81.75% |